News in the medical treatment of breast cancer

During the last decade, except for breast cancer, few "solid" tumours have benefited from significant progress in systemic treatment able to reduce the progression of metastases in advanced disease or to eradicate possible micro-metastases in the adjuvant situation. This review aims to gui...

Full description

Saved in:
Bibliographic Details
Published inBulletin du cancer Vol. 90; no. 1; p. 46
Main Authors Piccart, Martine, Dochy, Emmanuelle, Cardoso, Fatima
Format Journal Article
LanguageFrench
Published France 01.01.2003
Subjects
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Antineoplastic Agents - therapeutic use
Antineoplastic Agents, Hormonal - therapeutic use
Antineoplastic Agents, Phytogenic - therapeutic use
Breast Neoplasms - drug therapy
Enzyme Inhibitors - therapeutic use
Female
Humans
Paclitaxel - therapeutic use
Receptor, ErbB-2 - antagonists & inhibitors
Tamoxifen - therapeutic use
Trastuzumab
Online AccessGet more information

Cover

More Information
Summary:During the last decade, except for breast cancer, few "solid" tumours have benefited from significant progress in systemic treatment able to reduce the progression of metastases in advanced disease or to eradicate possible micro-metastases in the adjuvant situation. This review aims to guide the reader along the paths of the progress made in hormonotherapy, chemotherapy and targeted molecular therapy. For each category, the authors will attempt to estimate the impact of the therapeutic advances upon day-to-day clinical practice.
ISSN:0007-4551